Search research articles
Contact Us
Filters
Showing results (341-350 of 391) with videos related to
Page
of 40
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 24, 2025
Durvalumab versus physician's choice chemotherapy in recurrent ovarian clear cell adenocarcinoma (MOCCA/APGOT-OV2/GCGS-OV3): a multicenter, randomized, phase 2 trial
Natalie Y L Ngoi, Chel Hun Choi, Junxian Zhu, et al.
Clinical Genitourinary Cancer
|
June 23, 2026
Pembrolizumab and Denosumab in Clear-Cell Renal-Cell Carcinoma
Carole A Harris, Danka S Zebic, Michelle F Morris, et al.
Gynecologic Oncology
|
August 20, 2021
A phase 2 study of anastrozole in patients with oestrogen receptor and/progesterone receptor positive recurrent/metastatic granulosa cell tumours/sex-cord stromal tumours of the ovary: The PARAGON/ANZGOG 0903 trial
Susana N Banerjee, Monica Tang, Rachel L O'Connell, et al.
European Urology Oncology
|
July 20, 2025
Patient-reported Outcomes in KEYLYNK-010: Pembrolizumab Plus Olaparib Versus Abiraterone or Enzalutamide for Participants with Biomarker-unselected, Previously Treated Metastatic Castration-resistant Prostate Cancer
Niven Mehra, Emmanuel S Antonarakis, Se Hoon Park, et al.
Annals of Surgery
|
July 18, 2020
Proving the Effectiveness of the Fundamentals of Robotic Surgery (FRS) Skills Curriculum: A Single-blinded, Multispecialty, Multi-institutional Randomized Control Trial
Richard M Satava, Dimitrios Stefanidis, Jeffrey S Levy, et al.
BJU International
|
November 21, 2023
A phase II trial of nivolumab followed by ipilimumab and nivolumab in advanced non-clear-cell renal cell carcinoma
Ciara Conduit, Ian D Davis, Jeffrey C Goh, et al.
Nature Cancer
|
April 15, 2026
Predictive value of early PSMA upregulation for the response to enzalutamide ± <sup>177</sup>Lu-PSMA-617 in poor-risk, metastatic, castration-resistant prostate cancer: substudy of the randomized, phase 2 ENZA-p trial
Louise Emmett, Mina Swiha, Nathan Papa, et al.
The Lancet. Oncology
|
August 2, 2025
Prognostic and predictive value of baseline PSMA-PET total tumour volume and SUVmean in metastatic castration-resistant prostate cancer in ENZA-p (ANZUP1901): a substudy from a multicentre, open-label, randomised, phase 2 trial
Louise Emmett, Nathan Papa, Shalini Subramaniam, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 18, 2025
Pembrolizumab plus enzalutamide and androgen deprivation therapy versus placebo plus enzalutamide and androgen deprivation therapy for metastatic hormone-sensitive prostate cancer: the randomized, double-blind, phase III KEYNOTE-991 study
C Gratzke, M Özgüroğlu, A Peer, et al.
Oral Oncology
|
July 9, 2013
Consensus recommendations for management of head and neck cancer in Asian countries: a review of international guidelines
A D'cruz, T Lin, A K Anand, et al.
Page
of 40
Search research articles
Search
Showing results (341-350 of 391) with videos related to
Sort By:
Page
of 40
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 24, 2025
Durvalumab versus physician's choice chemotherapy in recurrent ovarian clear cell adenocarcinoma (MOCCA/APGOT-OV2/GCGS-OV3): a multicenter, randomized, phase 2 trial
Natalie Y L Ngoi, Chel Hun Choi, Junxian Zhu, et al.
Clinical Genitourinary Cancer
|
June 23, 2026
Pembrolizumab and Denosumab in Clear-Cell Renal-Cell Carcinoma
Carole A Harris, Danka S Zebic, Michelle F Morris, et al.
Gynecologic Oncology
|
August 20, 2021
A phase 2 study of anastrozole in patients with oestrogen receptor and/progesterone receptor positive recurrent/metastatic granulosa cell tumours/sex-cord stromal tumours of the ovary: The PARAGON/ANZGOG 0903 trial
Susana N Banerjee, Monica Tang, Rachel L O'Connell, et al.
European Urology Oncology
|
July 20, 2025
Patient-reported Outcomes in KEYLYNK-010: Pembrolizumab Plus Olaparib Versus Abiraterone or Enzalutamide for Participants with Biomarker-unselected, Previously Treated Metastatic Castration-resistant Prostate Cancer
Niven Mehra, Emmanuel S Antonarakis, Se Hoon Park, et al.
Annals of Surgery
|
July 18, 2020
Proving the Effectiveness of the Fundamentals of Robotic Surgery (FRS) Skills Curriculum: A Single-blinded, Multispecialty, Multi-institutional Randomized Control Trial
Richard M Satava, Dimitrios Stefanidis, Jeffrey S Levy, et al.
BJU International
|
November 21, 2023
A phase II trial of nivolumab followed by ipilimumab and nivolumab in advanced non-clear-cell renal cell carcinoma
Ciara Conduit, Ian D Davis, Jeffrey C Goh, et al.
Nature Cancer
|
April 15, 2026
Predictive value of early PSMA upregulation for the response to enzalutamide ± <sup>177</sup>Lu-PSMA-617 in poor-risk, metastatic, castration-resistant prostate cancer: substudy of the randomized, phase 2 ENZA-p trial
Louise Emmett, Mina Swiha, Nathan Papa, et al.
The Lancet. Oncology
|
August 2, 2025
Prognostic and predictive value of baseline PSMA-PET total tumour volume and SUVmean in metastatic castration-resistant prostate cancer in ENZA-p (ANZUP1901): a substudy from a multicentre, open-label, randomised, phase 2 trial
Louise Emmett, Nathan Papa, Shalini Subramaniam, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 18, 2025
Pembrolizumab plus enzalutamide and androgen deprivation therapy versus placebo plus enzalutamide and androgen deprivation therapy for metastatic hormone-sensitive prostate cancer: the randomized, double-blind, phase III KEYNOTE-991 study
C Gratzke, M Özgüroğlu, A Peer, et al.
Oral Oncology
|
July 9, 2013
Consensus recommendations for management of head and neck cancer in Asian countries: a review of international guidelines
A D'cruz, T Lin, A K Anand, et al.
Page
of 40